ArticleFrontiers in oncology2025
Burden of thyroid cancer in the older adult aged 60 and over from 1990 to 2021 and forecast of the situation in 2030.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This article aims to analyze the trends in global thyroid cancer mortality rate (ASMR) and disability adjusted life years (DALYs) from 1990 to 2021, and predict changes in disease burden by 2030. Through global data comparison and analysis, this study explores the impact of gender, age, and socioeconomic development level (SDI) on thyroid cancer mortality and disease burden. Method: This study is based on data from the Global Health Data Exchange (GHDx) and analyzes the trends of thyroid cancer deaths, age-standardized mortality rate (ASMR), and DALYs over the period from 1990 to 2021. The annual average rate of change (EAPC) of the data was analyzed using a joinpoint regression model. Additionally, stratified analyses were conducted by gender, age group, and SDI, and the burden of thyroid cancer for the year 2030 was projected. Result: Global thyroid cancer deaths increased from 2,198 in 1990 to 5,255 in 2021. Despite the rise in total deaths, ASMR remained stable at 0.07/100,000 for females and 0.05/100,000 for males. DALYs increased from 61,815 to 144,955, with an average annual growth rate of 0.38%. The burden on men rose significantly, while the increase was slower for women. Regions with higher SDI showed a slight decrease in burden, whereas low-SDI regions saw an increase, with an annual growth rate of 0.76%. Fiji had the highest burden, with an ASMR of 0.25 and AS-DALYs of 6.07. Female mortality and disease burden were higher than in males, particularly among those aged 85 and above. Conclusion: The global disease burden of thyroid cancer has been increasing, particularly in the older adult. While high-SDI regions experienced a decrease in burden, low-SDI regions saw an increase. Predictions suggest that by 2030, the mortality rate and disease burden may remain stable with slow annual changes. However, attention should be given to the growing burden in low-income areas and the impact of socio-economic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.